A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

ICI’s New Biorisk Cloud Platform Helps Organizations Protect their Workforces from Biorisk Threats

To help businesses, agencies and healthcare providers protect their people from biorisk threats, Infrared Cameras Incorporated (ICI) today unveiled its new Biorisk Cloud Platform.

Combining infrared technology and a proprietary, cloud-based data management solution, ICI helps organizations across industries report and manage biorisk, such as COVID-19, to avoid potential safety incidents and operational disruptions.

With accurate, real-time temperature readings, ICI’s platform streams data from thermal cameras to ICI’s proprietary cloud platform to identify biorisk patterns and threats before they cause operational issues like facility closures or shuttering of distribution centers. The cloud platform, supported by Amazon Web Services, can be readily integrated into an organization’s current business intelligence and operational platforms to help enhance reporting and improve safety and operational processes.

“Throughout the COVID-19 pandemic, organizations have realized tens of millions of lost operational hours due to outbreaks within their facilities,” said Gary Strahan, Chief Executive Officer at ICI. “Unfortunately, with new variants, including the extremely contagious Omicron variant, organizations will continue to be at risk of COVID-19 outbreaks within their facilities for years to come. Fortunately, ICI has developed a solution.”

According to the CDC, fever is the most common symptom of COVID-19 and is present in nearly 80% of cases. Through immediate, accurate identification of febrile individuals, organizations are able to mitigate exposure to COVID-19 and other infectious diseases.

“With nearly 90% of workers admitting to going to work while potentially infectious, outbreaks within organizations have become commonplace. These outbreaks lead to employee downtime, lower outputs, and a negative impact to an organization’s bottom line. Our platform helps organizations keep their people safe and their operations running smoothly,” said Strahan.

Texas Children’s Hospital, one of the largest and most comprehensive specialty pediatric hospitals in the U.S., is using ICI’s Biorisk Cloud Platform for temperature screening across its hospital, clinic and specialty care center locations.

“Providing extra protection for everyone in our facilities, we have deployed thirty cameras for screening employees across our buildings, tracking temperatures to help prevent anyone with COVID-19 from entering,” said Bert Gumeringer, Senior Vice President of Facilities Operations, Texas Children’s Hospital. “This type of screening is now a way of life. ICI is making it a smooth and efficient process for us and employee response has been fantastic.”

ICI’s platform is catered to an organization’s structure and processes, allowing them to communicate the most relevant data to each user.

Key features of the platform include:

  • Real-time, automated notifications;

  • Multifaceted analytics;

  • Customizable dashboards;

  • Ability to set benchmarks and identify deviations before they cause disruptions; and

  • Seamless integration with your organization’s current systems and processes including most access control and VM systems proprietary AI algorithms.

From design and implementation to calibration and training, ICI expert technicians service and educate customers every step of the way.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy